A Study Comparing the Combination of Trabectedin (YONDELIS) and DOXIL/CAELYX With DOXIL/CAELYX for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
NCT01846611
Completed
The purpose of this study is to assess the efficacy and safety of trabectedin+DOXIL as a third-line chemotherapy regimen (treatment) in patients with platinum-sensitive advanced-relapsed epithelial ovarian, primary peritoneal, or fallopian tube cancer who received 2 previous lines of platinum-based chemotherapy.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
03/29/2019
Locations: Not set, Phoenix, Arizona +3 locations
Conditions: Ovarian Neoplasms, Peritoneal Neoplasms, Fallopian Tube Neoplasms
Register for Updates
Effectiveness of Adventitial Dexamethasone in Peripheral Artery Disease
NCT01983449
Completed
To assess the safety and effectiveness of adventitial deposition of the Study Drug in reducing inflammation and restenosis in patients with clinical evidence of claudication or critical limb ischemia and an angiographically significant lesion in the superficial femoral and/or popliteal arteries. Study Drug and Dose: Dexamethasone Sodium Phosphate Injection, USP, 4 mg/ml, with dilute contrast (17%) administered to the adventitia in a dose of 1.6 mg per cm of desired vessel treatment length.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/06/2018
Locations: Arizona Heart Hospital / Abrazo Health Care Research / Tenet Health, Phoenix, Arizona +1 locations
Conditions: Peripheral Arterial Diseases
Register for Updates
Bioequivalence of Two Ciprofloxacin 0.3%/Dexamethasone 0.1% Sterile Otic Suspensions in Otitis Media in Children With Tympanostomy Tubes
NCT01994642
Terminated
The objective of this study is to compare the relative efficacy and safety of the test formulation of ciprofloxacin 0.3%/dexamethasone 0.1% sterile otic suspension (Par) to the already-marketed formulation CIPRODEX® (ciprofloxacin 0.3%/dexamethasone 0.1%) sterile otic suspension (Alcon) in the treatment of acute bacterial otitis media in children with patent tympanostomy tubes.
Gender:
ALL
Ages:
Between 6 months and 12 years
Trial Updated:
09/22/2017
Locations: Agave Clinical Ressearch, Mesa, Arizona +2 locations
Conditions: Otitis Media in Patients With Tympanostomy Tubes
Register for Updates
Combination Chemotherapy and Radiation Therapy in Treating Patients With Acute Lymphoblastic Leukemia That Has Relapsed in the CNS or Testes
NCT00096135
Completed
RATIONALE: Drugs used in chemotherapy work in different ways to stop cancer cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage cancer cells. Giving combination chemotherapy together with radiation therapy may kill more cancer cells. PURPOSE: This clinical trial is studying how well giving chemotherapy together with radiation therapy works in treating patients with acute lymphoblastic leukemia that has relapsed in the CNS and/or testes.
Gender:
ALL
Ages:
Between 18 months and 29 years
Trial Updated:
02/14/2017
Locations: Phoenix Children's Hospital, Phoenix, Arizona +1 locations
Conditions: Leukemia
Register for Updates
APF530 or Aloxi (Palonosetron Hydrochloride) Combined With Dexamethasone in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy for Cancer
NCT00343460
Completed
This randomized phase III trial is studying APF530 and dexamethasone to see how well they work compared with palonosetron and dexamethasone in preventing nausea and vomiting in patients receiving chemotherapy for cancer.
Gender:
ALL
Ages:
Between 18 years and 120 years
Trial Updated:
02/10/2017
Locations: Palo Verde Hematology Oncology - Glendale, Glendale, Arizona +1 locations
Conditions: Nausea and Vomiting, Unspecified Adult Solid Tumor, Protocol Specific
Register for Updates
A Bioequivalence Study of Two Ciprofloxacin/Dexamethasone Formulations in Patients With Otitis Externa
NCT01910155
Terminated
The objective of this study is to compare the relative efficacy and safety of the test formulation of ciprofloxacin 0.3%/dexamethasone 0.1% sterile otic suspension (Par Pharmaceutical Companies, Inc.) to the already-marketed formulation CIPRODEX® (ciprofloxacin 0.3%/dexamethasone 0.1%) sterile otic suspension (Alcon) in the treatment of acute bacterial otitis externa.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
10/14/2016
Locations: James Donivan Gordon, MD, Tucson, Arizona
Conditions: Otitis Externa
Register for Updates
A Study of Combination Thalidomide Plus Dexamethasone Therapy vs. Dexamethasone Therapy Alone in Previously Untreated Subjects With Multiple Myeloma
NCT00057564
Completed
To compare the efficacy of combination oral thalidomide plus oral dexamethasone treatment to that of oral dexamethasone-alone treatments as induction (first-line) therapy for subjects with active multiple myeloma
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/09/2015
Locations: Arizona Clinical Research Center, Tucson, Arizona
Conditions: Multiple Myeloma
Register for Updates
Dexamethasone Iontophoretic Patch for the Treatment of Pain Associated With Lateral Epicondylitis
NCT00794976
Completed
The objective of this study is to determine the safety and efficacy of a dexamethasone iontophoretic transdermal patch for the treatment of pain associated with lateral epicondylitis (tennis elbow).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/11/2015
Locations: Not set, Phoenix, Arizona +1 locations
Conditions: Lateral Epicondylitis, (Tennis Elbow)
Register for Updates
SWOG-9400 Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Patients With Previously Untreated Acute Lymphocytic Leukemia
NCT00002665
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with bone marrow transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more cancer cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy with or without bone marrow transplantation in treating patients who have acute lymphocytic leukemia.
Gender:
ALL
Ages:
Between 15 years and 65 years
Trial Updated:
03/05/2015
Locations: CCOP - Greater Phoenix, Phoenix, Arizona +3 locations
Conditions: Leukemia, Neutropenia, Thrombocytopenia
Register for Updates
S9805, High-Dose Melphalan Plus Peripheral Stem Cell Transplantation Followed by Interferon Alfa in Treating Patients With Waldenstrom's Macroglobulinemia
NCT00003416
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy and kill more tumor cells. Interferon alfa may interfere with the growth of the cancer cells. PURPOSE: Phase II trial to study the effectiveness of high-dose melphalan plus peripheral stem cell transplantation followed by interferon alfa in treating patien... Read More
Gender:
ALL
Ages:
69 years and below
Trial Updated:
03/05/2015
Locations: CCOP - Greater Phoenix, Phoenix, Arizona +3 locations
Conditions: Lymphoma
Register for Updates
S9922 Combination Chemo Plus Filgrastim With or Without Thalidomide in Refractory Multiple Myeloma
NCT00005834
Terminated
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Thalidomide may stop the growth of tumor cells by stopping blood flow to the tumor. It is not yet known if combination chemotherapy is more effective with or without thalidomide for multiple myeloma. PURPOSE: Randomized phase III trial to compare the effectiveness of combination chemotherapy with or without thalidomide in treating patients who have refractory multiple myeloma... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/05/2015
Locations: CCOP - Greater Phoenix, Phoenix, Arizona +3 locations
Conditions: Multiple Myeloma
Register for Updates
Dose Ranging Trial for Pixantrone in the FND-R Variant Regimen in Indolent Non-Hodgkin's Lymphoma
NCT00060684
Completed
The aim of this trial is to determine the appropriate dose of pixantrone to be used in this combination and obtain data on the combination's safety and activity profile.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/15/2015
Locations: Arizona Clinical Research Center, Tucson, Arizona
Conditions: Lymphoma, Low-Grade, Lymphoma, Small Lymphocytic, Lymphoma, Mixed-Cell, Follicular, Lymphoma, Small Cleaved-Cell, Follicular
Register for Updates